Hepatitis C virus: general property, drug treatment, drug resistance and mutation detection

Authors

  • Anchalee Sistayanarain Faculty of Medical Science, Naresuan University
  • Duangkamol Kunthalert Faculty of Medical Science, Naresuan University

DOI:

https://doi.org/10.14456/dcj.2022.21

Keywords:

hepatitis C virus, NS3, NS5A, NS5B, drug resistance

Abstract

Hepatitis C virus (HCV) is major course of hepatitis, cirrhosis and hepatocellular carcinoma. HCV infection occurs worldwide including Thailand. Hepatitis C virus are classified into 8 main genotypes and several subtypes. Genotypes 1-3 can be detected worldwide while genotypes 4-6 are found in some geographical areas. In Thailand, HCV genotype 3 is the most predominant (47.8%) followed by genotype 6 (34.8%) and 1 (17.4%). Treatment of HCV infection with conventional antiviral drugs encounters the limitation due to the serious side effects and drug resistance. Currently, direct-acting antivirals (DAAs) have been a promising approach for HCV therapy. DAAs are composed of NS3/4A protease inhibitors (PIs), NS5A inhibitors, NS5B nucleos(t)ide polymerase inhibitors (NIs) and NS5B non-nucleoside polymerase inhibitors (NNIs). However, drug resistance is also found to be associated with viral mutations. Detection of HCV gene mutations would be essential for the treatment. The popular method for the mutation assay is the investigating nucleotide sequence and amino acid sequence of NS3, NS5A and NS5B regions of HCV.

Downloads

Download data is not yet available.

References

Okamoto H, Miyakawa Y, Mayumi M. Molecular virology of hepatitis c virus. viral hepatitis rev. 1997;3:51-62.

Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, et al. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol. 1993;67:6152-8.

Evans MJ, Rice CM, Goff SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci USA. 2004; 101:13038-43.

Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 2008;4:e1000032.

Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 1996;15:12-22.

Chen M, Ma Y, Chen H, Dai J, Luo H, Jia M, et al. Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan China. PLoS One. 2019;e0217010.

Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-76.

Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, et al. Genetic characterization of hepatitis C virus strains in Estonia: Fluctuations in the predominating subtype with time. J Med Virol. 2007;79:374-82.

Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: Temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat. 2006;13:19-27.

Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31:61-80.

Chao DT, Abe K, Nguyen MH. Systematic review: Epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther. 2011;34:286-96.

Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5 and 6. Clin Gastroenterol Hepatol. 2005;3:S97-101.

Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Alshuth U, Rockstroh JK, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol. 2012;50:441-4.

Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol. 2013;5:496-504.

Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30-60.

Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016; 22:7824-40.

Vandelaer S, Hirankarn N. Prevalence of HCV infection at King Chulalongkorn Memorial Hospital. Chula Med J. 2018;62:67-78.

Sistayanarain A, Kunthalert D, Vipsoongnern Y. A shift in the Hepatitis C virus genotype dominance in blood donor samples from Thailand. Mol Biol Rep. 2011;38:4287-90.

Louisirirotchanakul S, Myint KS, Srimee B, Kanoksinsombat C, Khamboonruang C, Kunstadter P, et al. The prevalence of viral hepatitis among the Hmong people of northern Thailand. Southeast Asian J Trop Med Public Health. 2002;33:837-44.

Ishida T, Takao S, Settheetham-Ishida W, Tiwawech D. Prevalence of hepatitis B and C virus infection in rural ethmic population of northern Thailand. J Clin Viral. 2002;24:31-5.

Chunlertrith K, Sukeepaisarnjaroen W, Mairiang P, Urwijitaroon Y, Takase K, Yamauchi T, et al. Clinico-epidemiology of hepatitis C viral infection in northeastern Thailand. Southeast Asian J Trop Med Public Health. 2000;31:273-6.

Jatapai A, Nelson KE, Chuenchitra T, Kana K, Eiumtrakul S, Sunantarod E, et al. Prevalenceand risk factors for hepatitis C virus infection among young Thai men. Am J Trop Med Hyg. 2010;83:433-9.

Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA. 2005;102:2992-7.

Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology. 2015;62:1623-32.

Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol. 2012;26:487-503.

Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015;59:1505-11.

Bhatia M, Gupta E. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature. J Family Med Prim Care. 2020;9:531-8.

Downloads

Published

2022-06-29

How to Cite

1.
Sistayanarain A, Kunthalert D. Hepatitis C virus: general property, drug treatment, drug resistance and mutation detection. Dis Control J [Internet]. 2022 Jun. 29 [cited 2024 Nov. 18];48(2):239-47. Available from: https://he01.tci-thaijo.org/index.php/DCJ/article/view/249598

Issue

Vol. 48 No. 2 (2022): April-June

Section

Review Article

License

Copyright (c) 2022 Disease Control Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Disease Control Journal are considered as academic work, research or analysis of the personal opinion of the authors, not the opinion of the Thailand Department of Disease Control or editorial team. The authors must be responsible for their articles.